Kenyan Health Patient Information Leaflet
4-aminoquinoline antimalarial (ACT partner)
Acute malaria. It is effective against some chloroquine resistant strains of plasmodium falciparum. Clinical selection for Amodiaquine should follow culture results where relevant, Kenya STG/EML recommendations, and the current product SmPC. Class context: 4-aminoquinoline antimalarial (ACT partner). Confirm site-specific dose, duration and monitoring before prescribing.
Dosing is indication-, age-, weight- and organ-function-specific for this INN. Do not use class averages for high-risk patients. Confirm the exact regimen in the current SmPC and Kenya Standard Treatment Guidelines. Typical professional workflow: (1) confirm indication, (2) check renal/hepatic function, (3) screen interactions/allergies, (4) select dose/route/duration, (5) define monitoring.
Agranulocytosis and other blood dyscrasias, hepatitis, peripheral neuropathy, haemolytic anemia, nausea, vomiting, diarrhoea, lethargy. If frequently administered it may cause corneal deposits, visual disturbances, bluish-gray pigmentation of the fingernails, skin and palate. These disappear slowly after stopping treatment. Irreversible retinopathy after long-term therapy.
Store as labelled. Keep out of reach of children.